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Acute toxicity was defined as up to 18 weeks from the start 
of RT and was assessed using the modified RTOG toxicity 
criteria weekly during RT and then at week 10, 12 and 18. 
The NCI CTCAE v4 scoring system was used pre-RT and at 
week 18. Patients were also asked to complete IPSS 
questionnaires at these times. Peak toxicity grade (G) was 
dichotomized: modified RTOG G0&1 (n=13) vs G2&3 (n=37) 
and NCI CTCAE v4 (G0 vs G1&2). The Mann Whitney U test 
was used to compare toxicity groups using a range of 
dosimetric descriptors for each GU pelvic structure. Data was 
analysed in SPSS, v22 (IBM SPSS, Armonk, NY). 
 
Results: 36 patients (72%) experienced a peak G2 RTOG acute 
toxicity and 1 patient G3. At week 18, half of the patients 
had no toxicity according to the NCI CTCAE v4. IPSS median 
and IQR at pre-RT and 18 weeks (n=45) were 5 (4-9) and 7 (5-
9) respectively.  
There were statistically significant differences in a number of 
dose surface parameters for WB and BT using NCI CTCAE v4. 
No urethral dose parameters related to toxicity (Table 1). 
There were no statistically significant results for RTOG peak 
toxicity.  
 
Conclusions: Our technique to produce the dose surface map 
of the BT has enhanced the dosimetric information available 
for analysis of acute GU toxicity. The results suggest that 
modifying dose surface parameters to WB and BT may impact 
on the incidence of acute toxicity.  
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Purpose/Objective: Adjuvant hormonal therapy (AHT) 
improves the prognosis in intermediate-high risk prostate 
cancer treated with radiotherapy (RT). Luteinizing hormone-
releasing hormone(LH -RH) agonist represent the standard 
AHT, although this treatment is associated with several 
adverse effect. An alternative treatment, not based on 
pharmacological castration, might be represented by high-
dose antiandrogens (bicalutamide 150 mg / day). However, 
data comparing this treatments in terms of disease control 
are lacking. Therefore, aim of this study was to compare the 
results of two groups of patients who underwent AHT with 
LH- RH analogues or with bicalutamide, respectively. 
Materials and Methods: We analyzed data from three 
different clinical trials in which patients received 
radiotherapy (RT) and AHT with LH- RH agonist or high doses 
bicalutamide. The therapeutic choice was based on the 
urologist and/or patient preferences. Biochemical 
recurrence-free survival (according to Phoenix criteria), local 
control, disease- free and overall survival were assessed using 
the Kaplan-Meier method. Survival curves were compared by 
log-rank test ( univariate analysis ) and Cox's Proportional 
Hazard Method (multivariate analysis , considering as 
covariates : stage , pretreatment Prostate Specific Antigen, 
Gleason Score, duration of AHT, RT doses delivered to the 
pelvic lymph nodes). Patients were classified according to 
the National Comprehensive Cancer Network 2014 risk. 
Results: A total of 315 patients were included in the analysis. 
The 5 year results at univariate analysis are reported in the 
table.Multivariate analysis confirmed the lack of impact of 
type of AHT on biochemical recurrence -free survival (p= 
0.758). 
Conclusions: 
The results of this study showed no significant differences in 
terms of biochemical and clinical outcomes among patients 
undergoing adjuvant AHT with LH -RH agonist or 
antiandrogen. Based on the lower toxicity profile of 
antiandrogens , further prospective studies comparing these 
two therapeutic alternatives appear justified.  
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